Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes

Sarah A. Buchan, Hannah Chung, Kevin A. Brown, Peter C. Austin, Deshayne B. Fell, Jonathan B. Gubbay, View ORCID ProfileSharifa Nasreen, Kevin L. Schwartz, Maria E. Sundaram, Mina Tadrous, Kumanan Wilson, Sarah E. Wilson, Jeffrey C. Kwong the Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators
doi: https://doi.org/10.1101/2021.12.30.21268565
Sarah A. Buchan
1Public Health Ontario, Toronto, ON
2ICES, Toronto, ON
3Dalla Lana School of Public Health, University of Toronto, Toronto, ON
4Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hannah Chung
2ICES, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin A. Brown
1Public Health Ontario, Toronto, ON
2ICES, Toronto, ON
3Dalla Lana School of Public Health, University of Toronto, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter C. Austin
2ICES, Toronto, ON
5Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deshayne B. Fell
2ICES, Toronto, ON
6School of Epidemiology and Public Health, University of Ottawa, ON
7Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan B. Gubbay
1Public Health Ontario, Toronto, ON
8Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharifa Nasreen
2ICES, Toronto, ON
3Dalla Lana School of Public Health, University of Toronto, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sharifa Nasreen
Kevin L. Schwartz
1Public Health Ontario, Toronto, ON
2ICES, Toronto, ON
3Dalla Lana School of Public Health, University of Toronto, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria E. Sundaram
9Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mina Tadrous
2ICES, Toronto, ON
10Women’s College Hospital, Toronto, ON
11Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kumanan Wilson
12Department of Medicine, University of Ottawa, Ottawa, ON
13Bruyere and Ottawa Hospital Research Institutes, Ottawa, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah E. Wilson
1Public Health Ontario, Toronto, ON
2ICES, Toronto, ON
3Dalla Lana School of Public Health, University of Toronto, Toronto, ON
4Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey C. Kwong
1Public Health Ontario, Toronto, ON
2ICES, Toronto, ON
3Dalla Lana School of Public Health, University of Toronto, Toronto, ON
4Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, ON
14Department of Family and Community Medicine, University of Toronto, Toronto, ON
15University Health Network, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jeff.kwong@utoronto.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background The incidence of SARS-CoV-2 infection, including among those who have received 2 doses of COVID-19 vaccines, increased substantially following the emergence of Omicron in Ontario, Canada.

Methods Applying the test-negative study design to linked provincial databases, we estimated vaccine effectiveness (VE) against symptomatic infection and severe outcomes (hospitalization or death) caused by Omicron or Delta between December 6 and 26, 2021. We used multivariable logistic regression to estimate the effectiveness of 2 or 3 COVID-19 vaccine doses by time since the latest dose, compared to unvaccinated individuals.

Results We included 16,087 Omicron-positive cases, 4,261 Delta-positive cases, and 114,087 test-negative controls. VE against symptomatic Delta infection declined from 89% (95%CI, 86-92%) 7-59 days after a second dose to 80% (95%CI, 74-84%) after ≥240 days, but increased to 97% (95%CI, 96-98%) ≥7 days after a third dose. VE against symptomatic Omicron infection was only 36% (95%CI, 24-45%) 7-59 days after a second dose and provided no protection after ≥180 days, but increased to 61% (95%CI, 56-65%) ≥7 days after a third dose. VE against severe outcomes was very high following a third dose for both Delta and Omicron (99% [95%CI, 98-99%] and 95% [95%CI, 87-98%], respectively).

Conclusions In contrast to high levels of protection against both symptomatic infection and severe outcomes caused by Delta, our results suggest that 2 doses of COVID-19 vaccines only offer modest and short-term protection against symptomatic Omicron infection. A third dose improves protection against symptomatic infection and provides excellent protection against severe outcomes for both variants.

Competing Interest Statement

K.W. is CEO of CANImmunize and serves on the data safety board for the Medicago COVID-19 vaccine trial. The other authors declare no conflicts of interest.

Funding Statement

This work was supported by the Canadian Immunization Research Network (CIRN) through a grant from the Public Health Agency of Canada and the Canadian Institutes of Health Research (CNF 151944). This project was also supported by funding from the Public Health Agency of Canada, through the Vaccine Surveillance Reference Group and the COVID-19 Immunity Task Force. This study was also supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH). J.C.K. is supported by Clinician-Scientist Award from the University of Toronto Department of Family and Community Medicine. P.C.A. is supported by a Mid-Career Investigator Award from the Heart and Stroke Foundation. This work was supported by Public Health Ontario. This study was also supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). This study was supported by the Ontario Health Data Platform (OHDP), a Province of Ontario initiative to support Ontarios ongoing response to COVID-19 and its related impacts. The study sponsors did not participate in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication. Parts of this material are based on data and/or information compiled and provided by the Canadian Institute for Health Information (CIHI) and by Cancer Care Ontario (CCO). However, the analyses, conclusions, opinions and statements expressed herein are solely those of the authors, and do not reflect those of the funding or data sources; no endorsement by ICES, MOH, MLTC, OHDP, its partners, the Province of Ontario, CIHI or CCO is intended or should be inferred.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Section 45 of PHIPA authorizes ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system. Projects that use data collected by ICES under section 45 of PHIPA, and use no other data, are exempt from REB review. The use of the data in this project is authorized under section 45 and approved by ICES Privacy and Legal Office.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The dataset from this study is held securely in coded form at ICES. While legal data sharing agreements between ICES and data providers (e.g., healthcare organizations and government) prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS (email: das@ices.on.ca).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 28, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes
Sarah A. Buchan, Hannah Chung, Kevin A. Brown, Peter C. Austin, Deshayne B. Fell, Jonathan B. Gubbay, Sharifa Nasreen, Kevin L. Schwartz, Maria E. Sundaram, Mina Tadrous, Kumanan Wilson, Sarah E. Wilson, Jeffrey C. Kwong
medRxiv 2021.12.30.21268565; doi: https://doi.org/10.1101/2021.12.30.21268565
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes
Sarah A. Buchan, Hannah Chung, Kevin A. Brown, Peter C. Austin, Deshayne B. Fell, Jonathan B. Gubbay, Sharifa Nasreen, Kevin L. Schwartz, Maria E. Sundaram, Mina Tadrous, Kumanan Wilson, Sarah E. Wilson, Jeffrey C. Kwong
medRxiv 2021.12.30.21268565; doi: https://doi.org/10.1101/2021.12.30.21268565

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1096)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9772)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2312)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1561)
  • Health Policy (736)
  • Health Systems and Quality Improvement (603)
  • Hematology (238)
  • HIV/AIDS (504)
  • Infectious Diseases (except HIV/AIDS) (11649)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (238)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2144)
  • Nursing (134)
  • Nutrition (337)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1179)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2182)
  • Public and Global Health (4661)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)